National Pension Service increased its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 10.5% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 545,932 shares of the medical research company’s stock after purchasing an additional 51,978 shares during the quarter. National Pension Service owned approximately 0.07% of Amgen worth $94,222,000 at the end of the most recent reporting period.
A number of other hedge funds also recently added to or reduced their stakes in AMGN. Mn Services Vermogensbeheer B.V. increased its position in Amgen by 2.3% during the 1st quarter. Mn Services Vermogensbeheer B.V. now owns 19,884 shares of the medical research company’s stock worth $3,050,000 after purchasing an additional 450 shares in the last quarter. Pinnacle Advisory Group Inc. increased its position in Amgen by 12.5% during the 1st quarter. Pinnacle Advisory Group Inc. now owns 4,046 shares of the medical research company’s stock worth $664,000 after purchasing an additional 448 shares in the last quarter. Waldron LP acquired a new position in Amgen during the 1st quarter worth approximately $444,000. Carlton Hofferkamp & Jenks Wealth Management LLC acquired a new position in Amgen during the 1st quarter worth approximately $726,000. Finally, Osborne Partners Capital Management LLC increased its position in Amgen by 0.6% during the 1st quarter. Osborne Partners Capital Management LLC now owns 16,932 shares of the medical research company’s stock worth $2,778,000 after purchasing an additional 109 shares in the last quarter. Institutional investors and hedge funds own 78.10% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Amgen Inc. (AMGN) Shares Bought by National Pension Service” was first published by TrueBlueTribune and is owned by of TrueBlueTribune. If you are reading this story on another website, it was illegally stolen and reposted in violation of US and international copyright legislation. The correct version of this story can be accessed at https://www.truebluetribune.com/2017/10/01/amgen-inc-amgn-shares-bought-by-national-pension-service.html.
Shares of Amgen Inc. (NASDAQ AMGN) traded up 0.53% on Friday, reaching $186.45. 3,017,323 shares of the company traded hands. The stock has a market capitalization of $136.05 billion, a P/E ratio of 16.98 and a beta of 1.35. The stock’s 50 day moving average price is $175.99 and its 200-day moving average price is $169.31. Amgen Inc. has a one year low of $133.64 and a one year high of $191.10.
Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share for the quarter, beating the consensus estimate of $3.11 by $0.16. The business had revenue of $5.81 billion for the quarter, compared to analysts’ expectations of $5.67 billion. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The firm’s revenue for the quarter was up 2.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.84 earnings per share. Equities analysts forecast that Amgen Inc. will post $12.57 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Friday, September 8th. Investors of record on Thursday, August 17th were issued a $1.15 dividend. This represents a $4.60 annualized dividend and a yield of 2.47%. The ex-dividend date of this dividend was Tuesday, August 15th. Amgen’s dividend payout ratio (DPR) is currently 41.93%.
A number of equities research analysts have weighed in on AMGN shares. BMO Capital Markets lowered shares of Amgen from an “outperform” rating to a “market perform” rating and set a $199.00 target price on the stock. in a report on Friday, July 21st. They noted that the move was a valuation call. Credit Suisse Group boosted their target price on shares of Amgen from $177.00 to $186.00 and gave the stock an “outperform” rating in a report on Friday. Oppenheimer Holdings, Inc. reissued a “buy” rating and set a $203.00 target price on shares of Amgen in a report on Thursday, September 7th. Leerink Swann reissued a “market perform” rating and set a $161.00 target price on shares of Amgen in a report on Thursday, June 22nd. Finally, UBS AG set a $180.00 target price on shares of Amgen and gave the stock a “hold” rating in a report on Wednesday, July 26th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the company. Amgen currently has a consensus rating of “Buy” and an average price target of $188.41.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Amgen Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.